191 related articles for article (PubMed ID: 22074588)
41. Drug resistance in melanoma: mechanisms, apoptosis, and new potential therapeutic targets.
Grossman D; Altieri DC
Cancer Metastasis Rev; 2001; 20(1-2):3-11. PubMed ID: 11831644
[TBL] [Abstract][Full Text] [Related]
42. Advances in targeted therapy for unresectable melanoma: new drugs and combinations.
Hao M; Song F; Du X; Wang G; Yang Y; Chen K; Yang J
Cancer Lett; 2015 Apr; 359(1):1-8. PubMed ID: 25578781
[TBL] [Abstract][Full Text] [Related]
43. Locoregional therapies in melanoma.
Abbott AM; Zager JS
Surg Clin North Am; 2014 Oct; 94(5):1003-15, viii. PubMed ID: 25245964
[TBL] [Abstract][Full Text] [Related]
44. Management of metastatic melanoma 2005.
O'Day S; Boasberg P
Surg Oncol Clin N Am; 2006 Apr; 15(2):419-37. PubMed ID: 16632224
[TBL] [Abstract][Full Text] [Related]
45. Anticancer effect of terpenes: focus on malignant melanoma.
Wróblewska-Łuczka P; Cabaj J; Bargieł J; Łuszczki JJ
Pharmacol Rep; 2023 Oct; 75(5):1115-1125. PubMed ID: 37515699
[TBL] [Abstract][Full Text] [Related]
46. Adjuvant interferon-α for the treatment of high-risk melanoma: An individual patient data meta-analysis.
Ives NJ; Suciu S; Eggermont AMM; Kirkwood J; Lorigan P; Markovic SN; Garbe C; Wheatley K;
Eur J Cancer; 2017 Sep; 82():171-183. PubMed ID: 28692949
[TBL] [Abstract][Full Text] [Related]
47. Melanoma genetics: the other side.
Bis S; Tsao H
Clin Dermatol; 2013; 31(2):148-55. PubMed ID: 23438378
[TBL] [Abstract][Full Text] [Related]
48. Advances in the Understanding of Skin Cancer: Ultraviolet Radiation, Mutations, and Antisense Oligonucleotides as Anticancer Drugs.
Laikova KV; Oberemok VV; Krasnodubets AM; Gal'chinsky NV; Useinov RZ; Novikov IA; Temirova ZZ; Gorlov MV; Shved NA; Kumeiko VV; Makalish TP; Bessalova EY; Fomochkina II; Esin AS; Volkov ME; Kubyshkin AV
Molecules; 2019 Apr; 24(8):. PubMed ID: 30999681
[TBL] [Abstract][Full Text] [Related]
49. Three consecutive phase II studies of recombinant interferon alfa-2a in advanced malignant melanoma. Updated analyses.
Creagan ET; Ahmann DL; Frytak S; Long HJ; Chang MN; Itri LM
Cancer; 1987 Feb; 59(3 Suppl):638-46. PubMed ID: 10822463
[TBL] [Abstract][Full Text] [Related]
50. Itraconazole treatment of primary malignant melanoma of the vagina evaluated using positron emission tomography and tissue cDNA microarray: a case report.
Inoue K; Tsubamoto H; Isono-Nakata R; Sakata K; Nakagomi N
BMC Cancer; 2018 Jun; 18(1):630. PubMed ID: 29866134
[TBL] [Abstract][Full Text] [Related]
51. Carbon nanotubes in the diagnosis and treatment of malignant melanoma.
Naderi N; Madani SY; Ferguson E; Mosahebi A; Seifalian AM
Anticancer Agents Med Chem; 2013 Jan; 13(1):171-85. PubMed ID: 22721386
[TBL] [Abstract][Full Text] [Related]
52. High-dose interleukin-2 (IL-2) for the treatment of melanoma: safety considerations and future directions.
Marabondo S; Kaufman HL
Expert Opin Drug Saf; 2017 Dec; 16(12):1347-1357. PubMed ID: 28929820
[TBL] [Abstract][Full Text] [Related]
53. Management of metastatic melanoma.
Tawbi HA; Kirkwood JM
Semin Oncol; 2007 Dec; 34(6):532-45. PubMed ID: 18083377
[TBL] [Abstract][Full Text] [Related]
54. Ipilimumab induces simultaneous regression of melanocytic naevi and melanoma metastases.
Libon F; Arrese JE; Rorive A; Nikkels AF
Clin Exp Dermatol; 2013 Apr; 38(3):276-9. PubMed ID: 23020081
[TBL] [Abstract][Full Text] [Related]
55. Novel agents in development for the treatment of melanoma.
Tarhini AA; Agarwala SS
Expert Opin Investig Drugs; 2005 Jul; 14(7):885-92. PubMed ID: 16022577
[TBL] [Abstract][Full Text] [Related]
56. Feasibility of high-dose interferon-alpha2b adjuvant therapy for high-risk resected cutaneous melanoma.
Muggiano A; Mulas C; Fiori B; Liciardi G; Pintus M; Tanca L; Tedde A; Turno R; Desogus A
Melanoma Res; 2004 Apr; 14(2):S1-7. PubMed ID: 15057049
[TBL] [Abstract][Full Text] [Related]
57. Treatment for metastatic malignant melanoma: old drugs and new strategies.
Mouawad R; Sebert M; Michels J; Bloch J; Spano JP; Khayat D
Crit Rev Oncol Hematol; 2010 Apr; 74(1):27-39. PubMed ID: 19781957
[TBL] [Abstract][Full Text] [Related]
58. Current therapy of cutaneous melanoma.
Mays SR; Nelson BR
Cutis; 1999 May; 63(5):293-8. PubMed ID: 10349545
[TBL] [Abstract][Full Text] [Related]
59. [Advances in clinical treatment of malignant melanoma: B-RAF kinase inhibition].
Heneberg P
Klin Onkol; 2011; 24(4):256-64. PubMed ID: 21905615
[TBL] [Abstract][Full Text] [Related]
60. [Understanding current therapies in metastatic melanoma].
Rodríguez R; Parra A; González S; Molgó M; Droppelmann N; Acevedo F; Peña J; Uribe P
Rev Med Chil; 2016 Nov; 144(11):1448-1458. PubMed ID: 28394962
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
